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A B S T R A C T
Unprecedented efficacy of chimeric antigen receptor (CAR) T cell therapy in the treatment of hematologic
malignancies brings new hope for patients with many cancer types including solid tumors. However, the chal-
lenges for CAR-T cell therapy in eradicating solid tumors are immense. To overcome these seemingly intractable
hurdles, more “powerful” CAR-T cells with enhanced antitumor efficacy are required. Emerging data support
that the anti-tumor activity of CAR-T cells can be enhanced significantly without evident toxicity through si-
multaneous PD-1 disruption by genome editing. This review focuses on the current progress of PD-1 gene dis-
rupted CAR-T cells in cancer therapy. Here we discuss key rationales for this new combination strategy and
summarize the available pre-clinical studies. An update is provided on human clinical studies and available
registered cancer clinical trials using CAR-T cells with PD-1 disruption. Future prospects and challenges are also
discussed.
1. Introduction
Adoptive cell therapy (ACT) and immune checkpoint blockade have
radically changed the landscape of cancer treatment and provides new
hope and treatment options for cancer patients. Clinically, these im-
munotherapies have joined the ranks of surgery, radiation, and che-
motherapy as a pillar of cancer therapy [1]. Drugs that block the im-
mune regulatory checkpoints, i.e. programed cell death protein 1 (PD-
1), PD-ligands (PD-L1, PD-L2), and cytotoxic T cell lymphocyte-asso-
ciated antigen 4 (CTLA-4), have demonstrated impressive clinical out-
comes in a wide spectrum of hematological malignancies and solid
tumors, significantly improving overall survival. Indeed, immune
checkpoint inhibitors have emerged as frontline treatments for multiple
cancers, such as metastatic melanoma and non-small cell lung cancer
[2,3]. Adoptive transfer of chimeric antigen receptors (CARs) T cells has
also shown remarkable results in the treatment of cancers [4–6]. As a
result, the U.S. Food and Drug Administration (FDA) has recently ap-
proved the first two cell therapies, based on chimeric antigen receptor
(CAR) T cells, for B cell malignancies [7].
Mechanistically these two immune-oncological approaches are very
different. Immune checkpoint inhibition is aimed at releasing the
brakes that suppress the action of the immune system attack against the
tumor cells. Anti-PD-1 and PD-1-ligands, as well as anti-CTLA4 are
examples of this type of targeted approach, which are currently being
used as single agents or in combination with other therapies. The aim of
adoptive transfer of autologous T cells, modified ex vivo to express ar-
tificial CARs on the cell surface, is to create an immune effector spe-
cifically to attack cancer cells using the patient’s own immune system
[8,9].
Despite CAR-T cell therapy achieving remarkable results in the
treatment of hematological malignancies, treatment of solid tumors
using CAR-T remains an enormous challenge. The limited efficacy ob-
served is mainly related to poor trafficking, limited persistence and
infiltration, and T cell inhibitory activity in the tumor microenviron-
ment (TME) [10–14]. Therefore, it has been proposed that combina-
tional immunotherapy, combining CAR-T and immune checkpoint
blockade, may be a more efficacious treatment approach to solid tu-
mors [15–19]. To this end, over 75% of the immunotherapy clinical
trials registered at clinicaltrials.gov, combine PD-1/PD-L1 blockade
with at least one additional therapy [20].
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Although anti-PD-1 or PD-L1 monoclonal antibodies (mAbs) are
used to block the PD-1/PD-L1 regulatory axis in most clinical studies to-
date, cell-intrinsic disruption of immune checkpoints by gene editing in
CAR-T cells could be a better way to enhance the antitumor activity of
the CAR-T cells. This approach is more likely to elicit a better safety
profile than the systemic administration of blocking antibodies [21,22].
The most recent pre-clinical and clinical data demonstrated an im-
proved safety profile and tolerability with enhanced tumor control
capability in PD-1 disrupted CAR-T cells compared with the conven-
tional CAR-T [18,23–25]. Potentially, PD-1 knockout (KO) or disrup-
tion by precision genome engineering techniques in CAR-T cells could
be the next-generation of cell therapies used in solid tumor treatments
[18].
The clinical outcome of PD-1KO /disruption in T cells or CAR-T cells
by CRISPR (clustered regularly interspaced short palindromic repeats)
and CRISPR-associated (Cas) 9 in the treatment of various solid tumors
are being actively evaluated in multiple clinical trials. Up to September
26, 2019, the number of registered clinical trials using PD-1 KO/CAR-T
cells or PD-1 KO T cells was 20 (details in Table 1), including 4 from our
group (NCT03706326, NCT03525782 and NCT03525652 in https://
clinicaltrials.gov, and ChiCTR1900025088 from www.chictr.org.cn).
Comprehensive reviews discussing immune checkpoint blockades by
antibody and CAR-T therapies have been recently published elsewhere
[6,7,13,20,26–35]. This article provides the latest progress and avail-
able clinical data specifically in PD-1 KO/CAR-T for cancer treatment.
We also discuss the major clinical advantages and challenges of CAR-T/
PD-1 KO combination immunotherapy.
2. Immunotherapies based on PD-1 inhibition and CAR-T cells
2.1. The PD-1/PDL-1 axis
Ground-breaking science in the 1990′s showed human cells carry
specific proteins on their surface to evade attack from the host immune
system [36]. Cleverly, to escape attack from the body’s immune system,
human cells display some of these specific proteins on their cell surface,
thereby the immune system (including T cells, also known as T-lym-
phocytes) recognizes cancer cells as ‘self’. To survive cancer cells have
evolved multiple immunosuppressive mechanisms to avoid immune
detection, thus disarming many immunotherapeutic targets. The fast-
track understanding of the cell biology and signalling pathways that
cancer cells exploit to avoid immune detection and survive has allowed
for the development of new immunotherapies, which are at the leading
edge and a mainstay in the war against cancer. One of the key signalling
complexes, PD-1 interaction with PDL-1 (also known as B7-H1 or
CD274) and/or PDL2 (also known as B7-DC or CD273), is utilized by
cancer cells to evade T cell recognition and destruction. Disruption of
the PD-1/PD-L1 signalling complex is currently being used in cancer
immunotherapy in the clinic. PD-1 is a receptor protein on the surface
of T cells that binds to its’ ligands PD-L1 [37] or PD-L2 [38] on the
surface of host cells as a normal physiological response to prevent
cellular damage in response to chronic infection and inflammation
[39]. Hence PD-1 is known as a checkpoint molecule that participates in
self-recognition of normal cells in the immune surveillance response.
One of the duplicitous key mechanisms developed by the cancer cell to
avoid detection by T cells surveillance is by turning on the expression of
PD-L1 [40] or PDL-2 [41]. PD-L1 binds to PD-1 and serves as an
adaptive immune resistance, whereby cancer cells avoiding detection
and destruction [39,40]. The expression of PD-1 is commonly found on
tumor-infiltrating lymphocytes (TILs), immune cells that penetrate and
attack cancer cells compared to normal cells [42]. High expression of
PD-1 on TILs was found to be associated with impaired effector func-
tion, loss of tumor immune response, and poor prognosis [42]. Equally,
high PDL-1 expression on tumor cells was found to be associated with
poor tumor response and poor prognosis. In light of these findings,
blocking the PD-1/PDL-1 binding was proposed as an important
potential target for cancer therapy. There are a number of anti PD-1/
PD-L1 blocking mechanisms currently in the clinic, in clinical trials, or
in the development phase of discovery, mainly directed at the notor-
iously resistant, relapsed and metastatic cancers. Therefore, inhibition
of the PD-1/PD-L1 axis, either by PD-1 mAbs or PD-1 disruption in T
cells, has provided diverse opportunities to enhance antitumor im-
munity with the potential to produce durable clinical responses
[43,44].
2.2. Blocking the PD-1/PD-L1 axis using monoclonal antibodies
In 2008, the first PD-1/PDL-1 blocking strategy, monoclonal anti-
bodies (mAbs), were shown to be safe and well tolerated in a phase 1
clinical trial in patients with advanced hematologic malignancies [48].
Since conception of PD-1/PD-L1/PDL2 clinical trials over 2250 active
trials have been initiated (2006- September 2018) [49]. Most clinical
trials include combinations of anti-PD-1/PD-L1with other cancer
therapies, however, to-date only a few FDA approved combinational
therapies are available. These included nivolumab (anti-PD-1) with
ipilimumab (anti-CTLA-4), and pembrolizumab (anti-PD-1) with che-
motherapy [49], and more recently (2018) Cemipilmab (Libtayo) (anti-
PD-1) developed by Regeneron Pharmaceuticals. In addition, three FDA
anti-PDL-1 mAbs were approved but for specific cancer types, Atezoli-
zumab (Tecentriq), for urothelial carcinoma [50] and non-small cell
lung cancers (NSCLCs) [51,52], Avelumab (Bavencio) for metastatic
merkel-cell carcinoma [53]and Durvalumab (Imfinzi) [54,55] for ur-
othelial and unresectable NSCLC).
Advanced lung cancer, melanoma, breast cancer and lymphoma are
the most studied anti-PD-1/PD-L1 therapies tested, respectively. One of
the early clinical studies (2013) administering lambrolizumab
(Anti–PD-1) showed a promising high rate of sustained tumor regres-
sion with low grade adverse effects in patients with advanced mela-
noma [56]. The most extraordinary, efficacious clinical trial benefits to-
date are the combination of the dual checkpoint inhibitors, nivolumab
with ipilimumab in advanced melanoma (phase 1 dose escalation study:
CA209-004; phase II CheckMate 069; phase III CheckMate 067), with a
3-year overall survival (OS) rate of 63% [57,58]. The combinational
therapy resulted in a higher rate of survival compared to using mono-
therapy (nivolumab or ipilimumab), which included patient sub-groups
of PD-1 lowly expressing tumors [57,59]. Significant advances in
treatment outcomes (OS and PFS) have also been demonstrated in
clinical trials for mono- and combined advanced lung cancer patients
using FDA approved nivolumab [60–67], pembrolizumab [68–73] and
atezolizumab (anti-PD-L1) [51,74–77] and/or conventional che-
motherapies [78,79].
Common adverse effects in patients using anti-PD-1 mAbs treatment
include, skin rashes, liver, gastrointestinal tract, endocrine systems,
nausea, diarrhea, thyroid disorders, as reviewed in [80]. Other, more
serious PD-1/PD-L1-mAb associated autoimmune complications in-
clude cardiac complications [81,82], neuromuscular disorder [83], and
pneumonitis [84], requiring careful monitoring of patients during and
post PD-1/PD-L1 [85]. Although anti-PD-1 mAbs treatments for lung
cancers have had some positive results there has been considerable
serious concerns raised with deleterious side effects and increased risk
of mortality in some elderly patients [86–89]. Equally important, con-
tinuous treatment of PD-1 mAbs, potentiate a great risk of breaking the
patient’s immune tolerance and the host immune cells attacking normal
cells.
2.3. Chimeric antigen receptor (CAR) T cell therapy
The CAR-T cell therapeutic approach is a genetically engineered
ACT immunotherapy, using the host’s immunological defense system to
mount an attack on the cancer cell to treat cancer [90]. The engineering
of the CAR-T cells is described in detail in the article by Zhang et al
[91]. Autologous T cells are collected from the patient and genes are
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engineered into the T cells which are then expressed CARs on the sur-
face of the host T-cell. These gene inserts, CARs, are targeted to a
specific protein on the surface of the patient’s cancer cells. When in-
jected back into the patient, the CAR-T cells multiply, bind to, and kill
the tumor cells. In patients with relapsed or refractory B-cell acute
lymphocytic leukemia (ALL) CAR-T cell therapy showed promising re-
sults with long-term or complete remission in 80–90% of patients
[92–95]. Although CAR-T cell therapy has a number of adverse side
effects, which can be mild or severe, including cytokine release syn-
drome (CRS), (low blood pressure, flu-like symptoms, breathing diffi-
culties) and some patients have experienced some neurologic difficul-
ties, these symptoms are usually manageable.
2.4. Summary of CAR-T therapies for cancer
From bench to the clinic, CAR-T cell therapy has passed through
four generations since its initial development in 1989 [91]. The 1st
generation of CAR-T cell therapies, transfected with single-chain re-
ceptors, proved to be very disappointing in clinical trials for different
cancer types, with inadequate proliferation, short life-span and in-
adequate secreted proteins [91]. However, the 2nd generation of CARs
using three different receptor types, T-cell antigen receptor, cytokine
receptors and co-stimulatory receptors proved to be more efficacious
leading to FDA approval for treatment of refractory pre-B cell acute
lymphoblastic leukemia and diffuse large B cell lymphomas [6,96–98].
The 3rd generation of CAR-T cell therapies incorporated multiple sig-
naling domains to increase the potency by increasing the killing ability
through stronger cytokine manufacture [91]. Although these third
generation CAR-T cells were used to treat colon and lymphoma there
was little improvement in patient outcome in relation to the 2nd gen-
eration with some adverse clinical outcomes [99,100]. The 4th gen-
eration of CAR-T cells, named TRUCKS, produce an inducible trans-
genic ‘payload’ or protein which is released as an immune TME
modifier [101]. These ‘TRUCKs’ are aimed to attract and shape a fa-
vorable TME effectively by delivering chemokines/cytokines to the
cancer tissue. More recently the engineering of universal CAR
(UniCAR), which are switchable and reprogrammable platforms to re-
cognize more than one epitope are in the pipeline [102,103]. A major
stumbling block with CAR-T therapy is, whilst great progress is being
made with blood-borne cancers in the clinic [104], the solid tumors are
more difficult to penetrate, target and kill individual cancer cells. The
development of PD-1KO/with CARs is an interesting approach which is
providing some success in pre-clinical trials – the rationale for com-
bining PD-1KO and CARs in T-cell therapies is discussed.
3. Rationale for combining PD-1 knockout (KO) and CAR-T cell
therapy to treat solid tumors
Ninety percent of all cancer mortalities results from solid tumors
which are notoriously difficult to effectively treat [92,93]. Therefore,
the main battlefield for immunotherapy is the treatment of solid tu-
mors. Although the remarkable clinical outcomes of CAR-T cell therapy
in hematologic malignancies is driving the development of CAR-T cells
to target solid tumors, the challenges ahead are enormous. Currently
immune checkpoint inhibitors (ICIs) provides another new treatment
option. However, single-agent approaches are effective for only a select
subset of patients: therapies like checkpoint inhibitors have proven to
be effective in a fraction of the patients treated. For example, although
ICIs targeting PD-1 or PD-L1 now present as a standard treatment op-
tion for patients with advanced non-small-cell lung cancer (NSCLC) a
substantial proportion of patients will not benefit from these treatments
[105].
The overall rationale for CAR-T/PD-1 KO combination treatment is
to provide an enhanced version of CAR-T with stronger potency to fight
against solid tumors. The combination of CAR-T cells with PD-1
blockade through genetic modifications can significantly boost CAR-T
anticancer activities with a superior safety profile. The rapid advance-
ments in genome editing techniques, such as CRISPR and Cas9, has
enabled the use of genetic approaches to disrupted PD-1 function in
CAR-T-cells for cancer treatment.
3.1. Enhanced antitumor activity is required for eradication of solid tumor
by CAR-T cells
Despite very promising results observed in patients with relapsed or
refractory B-cell acute lymphocytic leukemia (ALL), showing long-term
or complete remission in patients (80–90%) [94,95] the therapeutic
application of CAR-T cells against solid cancers has limited efficacy due
to a number of therapeutic barriers. These barriers include CAR-T cell
infiltration, persistence, trafficking, and an unfavorable TME within
tumors [106,107]. These factors prevent CAR-T cells to effectively
contain solid tumor growth or eradicate tumors (discussed in 6.3. CAR-
T/PD-1 cell trafficking into solid tumors). In addition, solid tumors
exhibit heterogeneity with regards to intensity and distribution of
tumor-associated antigens (TAAs), posing additional challenges for
CAR-T-cell therapies [108]. This is a major encumbrance for CAR-T-cell
therapy when used as a single agent to treat solid tumors and is often
insufficient to mediate clinical tumor regression. To eradicate solid
tumors, or to achieve similar efficacy to that observed in homological
malignancies, combination of immune-checkpoint inhibitors and CAR-
T-cells have to be able to overcome many barriers, as mentioned above,
and infiltrate and remain in tumor tissues long enough to kill cancer
cells. Conventional CAR-T cells have limited capability to fight solid
tumors. Therefore, any strategy that can enhance the potency of CAR-T
cells will be of value. The combination of CAR-T with PD-1 blockade is
a promising strategy to enhance the antitumor activity of CAR-T cells
[45,47].
3.2. Combinational CAR-T and PD-1 blockade leads to enhanced antitumor
activity and a better safety profile
A large body of evidence supports that PD-1/PD-L1 interaction of T
cells and tumor cells leads to inhibition of T cell effector function [45],
coined T cell exhaustion [46]. As such, blocking this interaction with
PD-1 or PD-L1 mAbs or genetically engineering PD-1 KOs has the po-
tential to significantly enhance the anti-tumor activity of cytotoxic T
cells (CTLs) allowing T cell recognition of cancer cells and facilitating
eradication of tumor cells and reducing T cell exhaustion. In vitro and in
vivo PD-1 KO studies demonstrated CTLs were more efficient in killing
tumor cells when compared to the normal control CTLs [45,47]. The
antitumor activity of PD-1 KO CTLs was verified in vivo using a mouse
xenograft model [45]. These findings suggest that PD-1/PD-L1 disrup-
tion or blockade may be an effective strategy for improving the potency
of CAR-T cell therapies, especially in the treatment of solid tumors.
Mechanistically, PD-1 KO can enhance CAR-T cell anti-tumor activity
via removal of PD-1/PD-L1 and PD-1/PD-L2 signaling in these geneti-
cally edited immune T cells. Thus, inhibition of PD-1 expression on T/
CAR-T cells provides an opportunity for CAR-T cells to recognize tumor
cells [109]. Indeed, combination therapy comprising of CAR-T and PD-
1 blockade has been demonstrated to significantly enhance the anti-
tumor activity of CAR-T cells. Thus, pre-clinical data using CAR-T in
combination with PD-1 supports a promising immunotherapeutic
strategy for tumors: enhancing the antitumor efficacy and extending the
scope of patient treatment options [110]. Recently, reports have sug-
gested that CRISPR/Cas9-mediated disruption of PD-1 can boost the
function of CD19-CAR-T cells [18,111]. A summary of progress on the
pre-clinical studies on this combination therapy will be given in the
following sections.
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3.3. Issues surrounding current ICI blockade with systemic use of PD-1
mAbs
As mentioned above, PD-1 and its two natural ligands PD-L1 and
PD-L2 are responsible for delivering inhibitory signals that regulate the
balance between T cell activation, tolerance, and immunopathology
[44]. Inhibition of the PD-1/PD-L1 axis provides diverse opportunities
to enhance antitumor immunity with the potential to produce durable
clinical responses. Therefore, blocking the PD-1 pathway, either by PD-
1 mAbs or PD-1 KO T cells has emerged as a promising strategy for
cancer therapy.
Systemic administration of mAbs inhibitors is the most common
approach to block the known immune check points [35,112]. However,
systemic PD-1 Mab blockade is associated with a number of problems as
showed in Fig. 1. Firstly, toxicities due to enhanced activation of au-
toreactive T cells. Secondly, the blockade efficacy of PD-1 mAbs is
short-lived and relies upon repeated administration [47]. Thirdly, anti-
PD-1 mAbs can be captured prior to reaching the T cell surface by PD-1
tumor-associated macrophages through their Fc domain, removing
their ability to block PD-1 and resulting in suppression of T cell function
[113]. Fourthly, innate or development of resistance to checkpoint in-
hibitors may occur. Therefore, many patients do not experience a
complete response upon anti-PD-1 treatment, and some patients are
non-responders, highlighting the need to improve our understanding of
the molecular and cellular effects of blocking the PD-1/PD-L1 pathway
and the mechanism underlying adverse effects [114]. Finally, as re-
ported very recently, in some patients, mAbs binding to the PD-1 re-
ceptors on the tumor cells (lung cancer, melanoma, and liver cancer)
demonstrated the capacity to promote tumor growth [44,115], an un-
expected adverse effect of anti-PD-1 mAb treatment.
As a different technological approach to disrupting the PD-1/PD-L1
interaction, genetic modification, knocking out PD-1 gene in T cells, has
some advantages. This has been achieved through CRISPR editing of the
PD-1 gene [45]. In a mouse xenograft tumor model, introduction of
engineered PD-1/KO cytotoxic T lymphocytes (PD-1/KO/CTLs) re-
pressed tumor growth and increased survival outcome compared to
controls [45]. In April 2018, the first reported preliminary phase 1
clinical trials (NCT02793856), using infusion of PD-1 deficient CTLs for
non-small-cell lung cancer (NSCLC) showed promising results, with the
primary outcome being safety of use [116]. From the 8 patients en-
rolled in the study, low grade side effects were recorded, mostly fever
and hepatic dysfunction. Re-introducing a novel subset of engineered
PD-1 deficient TCLs allowed the immune-cells to recognize cancer cells
expressing PD-L1/PD-L2 receptors on the membrane surface and pro-
voking an immune-attack. Although to-date, there is not enough evi-
dential studies to support whether PD-1 immuno-editing of host T cells
is more beneficial or of equal benefit to treatments with PD-1 mAbs, in
the frontier point of view, cell-intrinsic disruption of immune check-
points by gene targeting in T cells is likely to display a superior safety
profile than the systemic administration of blocking antibodies [21].
Compared with combined CAR-T cell and anti-PD-1 mAbs treat-
ment, there are several advantages of using genetically engineered cells,
in which PD-1 gene is knocked out or disrupted. Recent studies de-
monstrated that ablation of Pdcd1 specifically in CAR-T cells might
provide a safer way to overcome tumor immunosuppression, particu-
larly when combined with TCR disruption to prevent activation of au-
toreactive T cells [18,117]. Combinational therapy using PD-1 KO and
CAR-T directed to specific cancers may prove to be more efficacious and
more tolerated than PD-1 KO or CAR-T individual therapies (refer to
section, PD-1 gene disrupted CAR-T cells).
3.4. Reliable precision genome editing is possible
The recent rapid advancement in genome editing technology has
enabled precision gene editing of T cells. The CRISPR-Cas9 system
confers targeted gene editing by small RNAs that guide the Cas9 nu-
clease to the target site through base pairing [118]. A number of studies
have shown that PD-1 gene KO/disruption in human T cells or CAR-T
cells using the CRISPR-Cas9 system can be accomplished with high
accuracy and success rates [17,18,22,24,119]. The combination of
CAR-T cells with PD-1 gene disruption by gene editing techniques has
led to observed enhancement of anti-tumor activities in liver cancer
[120], and B cell lymphoma [18].
These developments have provided the rationale for combining
adaptive cell therapy with PD-1 gene knockout modalities to improve
response rates and durability of responses in a variety of cancers [121].
Fig. 1. Adverse effects associated with Anti-
PD-1/PDL-1 mAb treatment. PD-1/PD-L1
blockade by monoclonal antibodies has be-
come a viable cancer treatment option.
However, systemic administration of PD-1
mAbs comes with a number of adverse effects
as listed. Many of these side effects can be
averted by PD1 gene knockout/disruption in
T cells by gene editing technology.
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4. Pre-clinical studies on PD-1 disrupted CAR-T cells
Pre-clinical studies directed towards disruption of the PD-1 gene in
human primary T cells and CAR-T cells, prior to the introduction of PD-
1 KO CAR-T therapies to cancer patients, are reviewed in this section.
4.1. PD-1 gene disrupted T cells
In view of the remarkable clinical results of systemic anti-PD-1 mAb
treatment, the PD-1 gene is the most promising target for T cell gene
editing. Mechanistically, PD-1 is expressed post T cell activation, and
binds to the corresponding ligand PD-L1 or PD-L2 on the surface of the
tumor cells, thereby inhibiting the transmission of T cell activation
signals [122]. The TME also contributes to promote high expression of
PD-1 on the surface of T cells and subsequently impairing their anti-
tumor function, which is an important feature of T cell exhaustion [46].
Therefore, disrupting the PD-1 gene in T cells through gene editing
technology should provide a promising strategy to overcome the hurdle
of immunosuppression in solid tumor treatment.
Although the CRISPR-Cas9 system is currently the most commonly
used method to edit genes in primary T cells, previously, zinc finger
nuclease (ZFN) and transcriptional activator-like effector nuclease
(TALEN) genome editing techniques were used to disrupt the PD-1. In
2015, Beane et al [123] found that in PD-1 KO in tumor infiltrating
lymphocytes (TILs) isolated from melanoma patients resulted in an ef-
ficiency of 75% using ZFN technology, and the bi-allelic mutation in-
cidence in the range of 40% to 48%, leading to 76% decrease in PD-1
expression on the T cell surface. In this study PD-1 KO did not alter the
T cell subsets and proliferation, resulting in a stronger antigen-specific
tumor cell killing and cytokine (TNFα, GM-CSF, and IFNγ) release in
vitro, compared to unmodified TILS. Using TALEN technology, Menger
et al. (2016) knocked out the PD-1 gene on tumor antigen-specific T
cells isolated from the melanoma and fibrosarcoma mice. They de-
monstrated that inactivation of the PD-1 gene in melanoma-reactive
CD8þ T cells and in fibrosarcoma-reactive polyclonal T cells enhanced
the persistence at the tumor site, and controlled the tumor progression
compared to the non-engineered T cells [124].
The CRISPR-Cas9 system as a gene-editing tool has advanced greatly
in recent years. This technology is becoming popular for T cell gene
editing, especially for PD-1 gene KO in human primary T cells
[45,119,125,126] and CAR-T cells [18,111,127]. Consistently, in all the
studies to-date, the antitumor effect of gene modified T cells/ CAR-T
cells has been found to be significantly enhanced. Su et al [119] was the
first to describe a non-viral mediated approach to KO the PD-1 gene in T
cells using electroporation of plasmids encoding sgRNA and Cas9. They
demonstrated an efficient disruption of gene PD-1 was achieved by
using the sgRNA: Cas9 system in T cells derived from both patients and
healthy donors. More importantly, disruption of the PD-1 gene by this
method resulted in significant reduction of PD-1 expression in T cells
but didn’t affect the proliferation of primary human T cells during the
prolonged 21 days in vitro culture. Gene modification of T cells also led
to favorable enhanced cytotoxicity, characterized by the up-regulation
IFN-γ production [119]. Using the same CRISPR-Cas9 system to KO PD-
1 in T cells, Zhao and colleagues found that introducing PD-1 KO-T cells
facilitated apoptosis and enhanced multiple myeloma cell death by 36%
compared with control. The enhancement of anti-tumor activity of the
PD-1 KO gene edited T cells was verified in vivo using a mouse xenograft
model. Xenografted mice with PD-1 KO T cells, demonstrated multiple
myeloma cell suppression and prolonged survival of the treatment an-
imals compared with the control group. PD-1 KO also increased T cell
secretion of TNF-α and IFN-γ by 2.4 and 1.9-fold respectively [45].
A different approach by Ligtenberg and colleagues [128] used a
novel self-delivering sdRNA to disrupt PD-1 in healthy donor T cells and
TILs from patient with malignant melanoma. Following treating with
sdRNA specific for PD-1, extracellular and intracellular PD-1 protein
levels in the majority of the human primary T cells were markedly
reduced. A significant increase in the capacity of T cells to secrete in-
terferon g (IFN-g) was observed upon polyclonal stimulation. They
further demonstrated that after expansion of PD-1 KO, TILs performed
with increased functionality against autologous tumors as compared to
control T cells. This method of introducing RNAi into T cells to disrupt
the expression of PD-1 receptors on the surface of T cells could readily
be applied to any ACT protocol to enhance the antitumor functions for
solid tumor therapies [128].
These results, summarized above, demonstrate the feasibility of
gene editing technology as an approach for efficient PD-1 disruption in
T cells, proposing a new strategy for targeting PD-1 or checkpoint in-
hibition as a clinical application.
4.2. PD-1 gene disrupted CAR-T cells
The success of knocking out the PD-1 gene in primary human T cells
using CRISPR/Cas9 raised the prospect of modifying PD-1 in CAR-T
cells in order to enhance their anti-tumor activity. As mentioned above,
the combination therapy of PD-1 mAbs with ACT is an attractive
strategy to break the immunosuppressive TME [16,129], given that
systemic administration of therapeutic PD-1 mAbs often cause adverse
effects by increasing autoimmune response. To avoid both PD-1-medi-
ated immunosuppression and the adverse effects of checkpoint
blockade by antibodies, PD-1 gene disruption in CAR-T cells may be a
promising approach. PD-1 KO improved antitumor efficacy of CAR-T in
various blood and solid tumor mouse models have been demonstrated
through enhancing effector function and survival of T cells in the TME
[18,130].
Rupp et al [18] successfully developed a method for combined
CRISPR/Cas9-based gene knockout and lentiviral transduction to gen-
erate PD-1 gene disrupted human CAR-T cells in one reaction. They
routinely obtained a 50% plus success rate in PD-1 gene knockout in
anti-CD19 CAR-T cells 48 h post-editing, as confirmed by flow cyto-
metry. In this study, they initially found that the expression of the in-
hibitory receptor PD-L1 on tumor cells could significantly inhibit the
activity of anti-CD19 CAR-T cells, resulting in impaired tumor clear-
ance. This directly confirmed the necessity of removing the PD-1/PDL-1
interaction in CAR-T cells. They further demonstrated that the PD-1
disrupted CAR-T cells significantly enhanced anti-tumor efficacy in vitro
and in vivo (tumor clearance rate of 17% for conventional anti-CD19
CAR-T cells increased to 100% in animals receiving PD-1 edited CAR-T
cells at 28 days post tumor implant).
Furthermore, in the study by Hu B et al [17], in one single reaction
they successfully used nucleofection to transfect plasmids encoding
both CRISPR/Cas9 to disrupt the PD-1 gene and the piggyBac transposon
system for expressing CD133-specific CAR, in human primary T cells.
The efficiency of CRISPR/Cas9-mediated genome editing in CD133-
specific CAR-T cells was validated by quantitative PCR and genome
sequencing. It was found that between 89.5 and 95% (average 91.5%)
of the PD-1 gene sites were disrupted. Their data showed that PD-1
disruption improved the in vitro cytotoxicity and the in vivo antitumor
activity in an orthotopic mouse model of glioma. Importantly, no evi-
dent toxicity induced by PD-1-deficient CAR-T cells was observed, re-
affirming the safety of PD-1 disrupted CD133-specific CAR-T cells, in
addition to the enhanced anti-tumor clinical efficacy. However, cyto-
kine (IFN-c, IL-2, TNF-a, and GM-CSF) secretion was not increased
when compared with that of conventional CAR-T cells, making it dif-
ficult to explain the improved anti-tumor function of the PD-1 disrupted
CAR-T cells.
In order to overcome the suppressive effect of PD-1 on CAR-T cells,
Hu et al [24] applied CRISPR/Cas9 system-mediated editing to disrupt
PD-1 gene locus in mesothelin-target CAR-T cells. As analyzed by flow
cytometry, a 59.2 ± 9.0% (n=6) reduction in the PD-1 expression
was observed in the PD-1 knockout mesothelin-CAR-T cells when
compared with the conventional Meso CAR-T cells. Although it had
little effect on CAR-T cell proliferation, the reduction significantly
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increased cytokine (IFN-γ and IL-2) formation, as measured by in-
tracellular cytokine staining, compared with control CAR-T cells.
Stronger in vitro cytotoxicity of PD-L1-expressing cancer cells was also
evidenced in the PD-1 gene edited CAR-T cells. The in vivo anti-tumor
effect of PD-1 disrupted CAR-T cells was studied in an orthotopic xe-
nograft mouse model utilizing BT-549 cells stably expressing luciferase.
The results demonstrated that PD-1 KO through CRISPR Cas9 enhanced
the antitumor activity of CAR-T cells against triple-negative breast
cancer (TNBC), presented as a solid tumor. In this model, PD-1 dis-
ruption was superior to PD-1 blocking antibody in improving the an-
titumor effect of CAR-T cells when combined together.
Using the CRISPR/Cas9 gene-editing system, Guo et al [120] dis-
rupted PD-1 gene in the Glypican-3 (GPC3)-targeted CAR-T cells and
explored the in vitro and in vivo antitumor efficacy of PD-1-deficient
CAR-T cells against liver cancer, one of the most immunosuppressive
cancer types. In their comprehensive study, the upregulation of PD-L1
expression was observed on the hepatocellular carcinoma (HCC) cells
exposed to the GPC3-CAR-T cells. Subsequently, they demonstrated that
disruption of PD-1 significantly enhanced anti-tumor efficacy of PD-1-
deficient CAR-T cells against HCC. Mechanistic studies showed that PD-
1 deficient GPC3-CAR-T cells have a greater ability to survive, in-
dicating protection from exhaustion when combating native PD-L1-
expressing HCC. Improved in vivo persistence and infiltration of PD-1
gene edited CAR-T cells was also observed in the xenograft tumor
model. The study shed light on the potential of precision gene editing
on the immune -checkpoints to augment the CAR-T cell HCC therapies.
Recently, Liu et al [131] developed new methods to carry out
multiplex gene editing of TRAC, B2M, and PD-1 in CAR-T cells based on
the CRISPR-Cas9 system. In the PD-1 KO CART cells, the PD-1 expres-
sion on the CAR-T cell surface was significantly decreased while the
proliferation and immune phenotype were not altered. The gene edited
CAR-T cells demonstrated a stronger anti-tumor effect both in vivo and
in vitro. Their studies illustrated, the advantage of using the CRISPR-
Cas9 platform. Multiple genes could be knocked out simultaneously
and, as such, enabling a multiplex gene editing technique readily ap-
plicable to CAR-T cells, resulting in a promising immunotherapy pro-
duct for cancer treatment [111,131–133].
The advantage of combining PD-1 disruption with CAR-T cell
therapy has been highlighted in studies described above. The results
thus far have been very promising and have led to an increasing number
of clinical studies. However, in some studies [134] PD-1 KO T cells
presented some problems. For example, although PD-1 KO showed fa-
vorable enhanced short-term proliferation and cytotoxic effects, PD-1
gene edited T cell were susceptible to T cell exhaustion and lacked long-
term durability. Therefore, further well-designed follow-up studies and
clinical validation are needed to fully understand the therapeutic po-
tential of PD-1 gene knockout or disruption [134].
5. Data from human clinical studies and ongoing clinical trials
Pre-clinical studies, as outlined above, have demonstrated that re-
cent advances in gene editing technology has enable us to precisely and
intrinsically modify the immune check-point PD-1 gene on the CAR-T
cells to enhance antitumor activity. The strategy of using PD-1 KO CAR-
T cells to treat cancer has clear advantages. It would prevent potential
toxicity associated with systemic anti-PD-1 or anti-PD-L1 administra-
tion (e.g. opportunistic autoimmunity) while avoiding interfere with
normal homeostatic functions of these ICP molecules within the body.
The full potential of this approach would need to be explored and va-
lidated through rigorous clinical trials.
Although clinical trials evaluating the safety and efficacy of infusing
autologous CD4+ T cells with CCR5 gene KO in patients with chronic
HIV infection commenced a decade ago (2009) (NCT00842634,
NCT01044654), the first case of CRISPR gene editing tested in cancer
patients did not begin until 2016 [135]. The first clinical trial of
CRISPR/ Cas9 uses CRISPR/Cas9 mediated PD-1 KO T cells in patients
with lung cancer [135]. Subsequently, similar clinical trials with PD-1-
knockout autologous T cells are underway for prostate cancer
(NCT02867345), bladder cancer (NCT02863913) and renal cell carci-
noma (NCT02867332). Now clinical trials using PD-1 deficient CAR-T
cells are being conducted for lung cancer (NCT03525782), Acute
Lymphoblastic Leukemia (ALL), Burkitt Lymphoma (NCT03298828),
oesophageal cancer (NCT03706326), prostate cancer (NCT03525652),
refractory B cell malignancies (ChiCTR1800020306), and various solid
tumors (NCT03747965, NCT03545815). The safety and efficacy of PD-
1 KO modified T cells and PD-1 KO CAR-T cells in the treatment of
cancer patients are being actively evaluated.
All clinical trials registered in Clinicaltrial.gov and www.Chictr.org.
cn, using PD-1 knockout primary T cells and CAR-T cells for cancer
treatment are summarized in Table 1.
At present, most of the above clinical trials have not reported their
findings to-date. Among all of these registered trials, only three of them
have reported preliminary findings. Jin et al [136] investigated the
safety and activity of PD-1 KO primary T cells in patients with advanced
esophageal squamous cell carcinoma (ESCC, n=21). After PD-1 was
knocked out by CRISPR)/Cas9 system, T lymphocytes were expanded
and reinfused back to the patients. In this study, they found that the
most common adverse events were transient fever (7 patients, the
highest was 39.1℃) and chills (3 patients) and moderate skin rash (1
patient), among the 21 treated ESCC patients, with no grade 3 or 4
adverse events observed. Only limited efficacy data was made avail-
able. Disease control rate and median overall survival was reported to
be 35% (6/17) and 127 days, respectively. They also showed that the
PD-1 knockout T cells infiltrated into and persisted for a durable time in
ESCC that responded to therapy. Lu and colleagues [116] conducted the
first-in-man clinical trial (NCT02793856) to assess the safety of
CRISPR/Cas9-mediated knockout of PD-1 gene in autologous T lym-
phocytes in patients with advanced non-small cell lung cancer (NSCLC).
They used an escalating dosage scheme on 11 patients. From the data
collected from 8 patients, who received 16 cycles of PD-1 KO T cells
infusions, they found that the most common adverse effects were acute
fever and hepatic dysfunction (both 15.4%). No DLT and 3–5 grade
adverse effects were noticed, again reassuring the safety of the PD-1 KO
T cells in patients. Using the next generation sequencing, they observed
evidence indicating the existence of potential responsive T cell clones in
patient peripheral bloods during the cell therapy. Our updated ob-
servations from 8 enrolled patients with advanced NSCLC treated with
PD-1 deficient MUC1 targeted CAR-T cells, showed low rates of adverse
events during the MUC1-CAR+/PD-1-KO therapy, reported at the 2018
ESMO Immuno-oncology Congress. No grade 3–5 adverse effects were
observed, indicating excellent tolerability of the PD-1 KO product.
Preliminary data supported a moderate treatment response in patients
during the low dose regimen. Complete efficacy data are still being
collected.
All these available human clinical data currently support that cancer
treatment with PD-1 KO T cells or PD-1 deficient CAR-T cells are safe,
with no major safety concerns detailed to-date. Further clinical studies
are required to ascertain the safety and efficacy of the CRISPR/Cas9-
mediated PD-1 KO in primary T cells and CAR-T cells, as no safety
profile can be estimated using computer programs with clinical trials.
We await updated results from more clinical studies.
6. Challenges
While the advantages and importance for combinational PD-1 dis-
ruption and CAR-T cells are showing promise, there are still many
technological challenges for PD-1 disrupted CAR-T cells, especially for
solid tumors where the TME is unfavorable for conventional CAR-T cell
therapy. Both CAR-T cells for the treatment of solid tumor and CRISPR/
Cas9 for genome editing for primary T cell are still in their infancy.
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6.1. Challenges in CAR-T cell design and therapy
Effective CAR-T cell-based therapy need to address five major
classes of functional challenges [14]. Firstly, trafficking to the site of
the tumor is a significant issue for solid tumors treatment. It appears
that relatively little work has been done to design strategies for im-
proving trafficking. Secondly, tumor target recognition of CAR-T cells is
critical for the killing of tumor cells. Finding more efficient targets or
combined targets are needed address this issue. Thirdly, the prolifera-
tion and persistence of CAR-T cells influence their clinic efficacy. Thus,
increase of proliferation of healthy CAR-T cells is a major focus area of
current research. Fourthly, overcoming the TME since many solid tu-
mors have an immunosuppressive TME. Previous work has validated
that the immunosuppressive TME is an important factor limiting the
wider applications of CAR-T cell therapy. PD-1 deficient CAR-T is an
effective strategy to overcome the suppressive TME. Finally, the strin-
gency of the manufacture of the CAR-T cell product is critical for this
type of personalized treatment. Uncontrolled CAR-T cell response has
typically been shown to lead to severe toxicity and adverse side effects
[137]. A recent report tracked a patient’s resistance to CAR-T therapy
and subsequent relapse to a single anti-CD19 CAR genetically en-
gineered leukemic B-cell introduced during T cell production [138].
However, this incidence is believed to be a rare event highlighting the
need for stringent Good Manufacturing Practice (GMP). In the case of
CAR-T cell preparation for solid tumors the incidence of this type of
error is hardly applicable.
6.2. Technical challenges of CRISPR-Cas9 to clinical translation
Genome editing with CRISPR-Cas9 holds immense therapeutic po-
tential for improving T cell-based immunotherapy. However, T cell
therapy based on genome editing, still faces some challenges for com-
plete clinical applications [139,140]. The issue of priority is the safety
of genetically engineered T cells. In view of this, some studies have
attempted to increase the specificity of gene editing with minimal off-
target effects, but the degree of accuracy still needs to be determined for
specific clinical applications. Another challenge is the fitness of edited
cells and the therapeutic threshold of editing. If the edited cells possess
a greater capability to proliferate or show greater adaptability than the
unedited cells, this will facilitate the edited product to reach the ther-
apeutic threshold required for successful treatment outcomes. In addi-
tion, it is not clear how the autoimmune system will response to ge-
netically engineered cells. Extensive research and encouraging results
from the use of universal CAR-T therapy in clinical applications have
shown that T cell therapy with CRISPR-Cas9 technology will increase
the efficacy, with a broader spectrum of patient-targeted treatment.
Therefore, although with some challenges, we envision continued ad-
vancement of CRISPR-Cas9 technology will lead to more specific cancer
therapeutic applications in the future.
In the past, effective genome engineering of primary T cell was
unachievable due to low transfection efficiencies. But recent advances
in electroporation tools as well as T cell activation methods allow
highly efficient gene editing in primary T cells. However, there are still
challenges remaining in current T cell engineering methodology. First,
CRISPR/ Cas9-mediated gene-editing can induce apoptosis and growth
retardation in engineered T cells, partially attributable to p53-mediated
DNA damage and type I interferon responses [130,141,142]. Although
PD-1 KO showed favorable enhanced short-term proliferation and cy-
totoxic effects, PD-1 gene edited T cell were still shown to be suscep-
tible to T cell exhaustion and lacked long-term durability. Therefore,
further well-designed follow-up studies and clinical validation are
needed to fully understand the therapeutic potential of PD-1 gene
knockout or disruption [134].
6.3. CAR-T/PD-1 cell trafficking into solid tumors
The TME provides a particularly hostile suppressive environment
for the immune response team, by providing a physical barrier and
secreting suppressive cytokines, reviewed in [143]. A number of stra-
tegies have been designed to overcome the major hurdle of infiltration
and survival of CAR-T cells in solid tumors, from injection of CAR-T
cells directly into the tumor site to engineering the T cells to stimulate
anti-tumor properties, reviewed in [144]. To enhance infiltration into
the solid tumor one approach was to engineer a heparinase enzyme into
the CAR-T cell enabling the degradation of the rich stromal- extra-
cellular matrix of the tumor [145]. As newly formed vasculature is a
significant feature of solid tumors, CAR-T cell targeting or ‘homing-in’
on receptors on newly formed blood vessels, such as the vascular en-
dothelial growth factor receptor-2 (VEGFR2) [146], integrin alpha v
beta 3 [147], or perturbation of vascular endothelin-B-receptor (ETBR -
decrease) and endothelin-A-receptor (ERAR - increase) [148], have
demonstrated promising results in pre-clinical experimentation. Im-
portantly, using checkpoint inhibitors, like PD-1 mAbs and PD-1 dis-
ruption helps T cell activation and tumor death, with even greater ef-
ficacy when combined with enhancer effector molecules such as the
A2AR antagonist (blocking the adenosine immunosuppressive
pathway), granzyme B and interferons, reviewed in [144]. The highly
metabolic, hypoxic, conditions of the solid tumor also contributes to the
unfriendly immune unresponsiveness of CAR-T cell therapies. The de-
pendence on glycolysis by the highly proliferative tumor cells leads to
excess production of lactic acid reducing the availability of essential
nutrients (glucose and amino acids) [149,150]. The accumulation of
metabolic waste by-products from the cancer cell are detrimental to T
cell function [151], thus potentially impairing CAR-T cell therapeutic
action. PD-L1 expression on the tumor cell not only acts as a handshake
to evade T cell recognition, it is involved in many activities to protect
the cancer cell from immune attack and destruction including PD-L1
upregulation of glycolysis genes and increased glycolysis [152]. Ten-
tatively, by disrupting the PD-1/PD-L1 signaling there is a distinct
possibility of change of PD-L1 metabolic function. Linking CAR-T/PD-1
cell immune-therapy with metabolic reprogramming of the cancer cells
targets two of the major hallmarks of cancer (disruption of the immune
system and metabolism).
Poor infiltration of T-cells into solid tumors has been a major
stumbling block for CAR-T cells therapies. Recent development in this
area comes from the preclinical use of a penetrating peptide iRGD in
synergy with PD-1/KO to provide a superior therapeutic outcome, as
evaluated recently for gastric cancers [153].
6.4. Controlling potential enhanced auto-immune response
Continuous development of CAR-T, checkpoint inhibition tech-
nology is paramount to addressing many concerns around efficacy,
safety of use and ethical concerns raised. The CAR-T cells can multiply
in the host and, as reported by Kenderian’s group, they have the ca-
pacity to differentiate into memory cells remaining up to 4 years in
some patients [154]. This has a double-edged effect, the engineered
CAR/PD-1KO T-cells may have a long-term positive effect in combating
specific tumor cells, conversely, presence of these manufactured T-cells
may promote or enhance an auto-immune response. To overcome some
of the problems of short- and long- term, known and unknown adverse
side effects of CAR-T-cell therapy is the introduction of suicide genes.
Manufacture of CAR-T cells with ‘off-switches’ can limit the time span
of CAR-T-cell survival and also reduce the severity of side effects such
as CRS. To this effect, technology such as precision engineering of the T
cells by the insertion of inducible suicide genes such as caspase9 (iC9)
[155] or co-expression of CAR-T and suicide genes [156] are under
development.
To combat the problem of on- or off- target effects, these can po-
tentially be minimized by simultaneously using two tandem CAR tumor
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antigens, or one tumor antigen one normal antigen which inhibits the
activity of the tumor antigen, described in [30]. The possibility of un-
wanted mutations through CRISPR integration is also being addressed
through designed RNA-guided recombinase-Cas9 fusion technology to
target genomic DNA deletion and integration and bypass the host T-cell
endogenous DNA repair mechanism [157].
6.5. Reducing manufacturing costs and broader application
Major challenges of translating CAR-T-based therapies into the
clinic are the time of manufacture and the high costs involved.
Currently, the individualization of CAR-T treatment and the cost of
biomanufacturing technology of CAR-T/PD-1 is prohibitive for large
scale clinical application. In recent years, the biomanufacturing tech-
nology (such as manufacturing process automation) of CAR-T based
therapeutic products has been significantly shortened from two weeks
to one day [158,159]. This technological advancement provides a
greater window of survival opportunity, offering rapid more cost-ef-
fective treatment to patients with advanced cancer. Individual patient
expansion of autologous CAR/PD-1KO T-cells are expensive to manu-
facture and demands high quality control (GMP facilities) and are time
consuming. Also, to reduce cost and increase manufacturing pro-
ductivity, alternative simple and affordable alternatives for large scale
CAR-T manufacture using non-viral gene transfer methods such as the
Sleeping Beauty [30,160–162] and PiggyBac transposon/transposase
[163] are under consideration.
6.6. Using allogeneic ‘off the shelf” CAR-T/PD-1KO cells
The use of allogeneic, universal CAR-T ‘off-the-shelf’ based therapies
are also being actively researched, although the safety of using donor
(graft) versus host (GVHD) T cells is challenging, reviewed in [164]. In
vitro and in vivo experimentation of allogeneic CAR-T PD-1 cells defi-
cient in PD-1, human leukocyte antigen (HLA) class 1 molecule and
TCR (using multiplex genome editing) to reduce alloreactivity (the risk
of immune rejection by the host or GVHD) may be an alternative 'off-
the-shelf’ strategy to reduce costs, time of production-to-clinical ap-
plication [133]. Also, the combination of TCR and CD52, down-
regulation of CD3/TCRαβ, has demonstrated promise in CAR-T cell
production [165]. To increase flexibility in antigen recognition a split
universal and programmable (SUPRA) CAR system has been developed,
which incorporates a dissociable antigen recognition motif targeting
multiple antigens [165]. More recently, Lee and colleagues recently
published a method to expand clinical-grade allogeneic T cells to be
used as an ‘off-the-shelf” ACT to target different cancer types [166]. In
this report, these ‘of-the-shelf’ engineered cells in pre-clinical models
demonstrate no apparent off-tumor toxicity, does not induce host-
versus-graft reaction and can be cryopreserved, ready for use.
6.7. Ethical concerns with CAR-T and PD-1 therapy
There are a few generic ethical concerns for genetically manipulated
gene-transfer technology still to be resolved [167]. To-date, un-
certainties still exist as to how exactly the autoimmune system will
respond to the genetically engineered CAR-T cells, as mentioned above.
The most conspicuous ethical challenge facing clinical application of
genetic-based therapies, such as PD-1 KO/CAR-T cell, is the long- and
short- term associated risks for the patient, which are currently too
early to assess due to newness of the technology [167]. Evaluation of
the present risk is questionable, mainly because the early dramatic ef-
ficacy of CAR-T cell treatments has not been fully assessed against
safety risks. Increased quality of life in patients receiving CAR-T
therapy with no other viable treatment options often delays relapse
onset with development of resistant cancer cells within 6 months of
treatment [168].
Ethical concerns on the credibility of gene-transfer has also been
raised in the context of conflict of interest between the pharmaceutical
companies, research institutes and investors [169]. Further, the issue of
publication bias has been raised questioning the credibility of pre-
clinical studies used as evidence for the basic move from laboratory into
the first in-human Phase 1 gene editing cancer trials [169]. In summary,
the advantages of immune-based therapies for advanced cancers, where
little hope exists, out-ways the currently known adverse effects. Re-
ference to acute pharmacovigilance to avert immediate acute toxicities,
and undefined long-term impacts continues to be important for the
assessment of clinical outcomes of the new treatments.
7. Concluding remarks and future direction
It is exciting to witness the speedy advancement of CAR-T cell
therapies, ICI therapies and gene editing technology such as CRISPR-
Cas9 in combination therapies to combat solid tumor as well as he-
matological-based tumors. Combining PD-1 blockade and CART into a
single therapy is a promising strategy and has the potential to be a more
effective treatment for solid tumors. Although it is in its infancy, con-
siderable pre-clinical evidence supports that PD-1 gene disrupted CAR-
T cells significantly improves the antitumor activity and safety profile,
while the features of T cell proliferation and subsets are retained. The
most encouraging phenomena is a significant enhancement in the in
vitro and in vivo antitumor activities of CAR-T cells with disrupted PD-1
gene, which have been consistently observed in all pre-clinical studies.
The enhanced antitumor activity is closely associated with the inter-
rupted PD-1 expression on CAR-T cells, reaffirming the importance of
blocking PD-1 axis using this new approach. Other mechanism under-
lying the enhanced antitumor property of PD-1 deficient CAR-T cells
may be related to increased secretion of cytokines such as IFN-γ and IL-
2 (Fig. 2). Despite some technical challenges and some ethical concerns,
as discussed, a number of clinical trials are under way using PD-1
knockout CAR-T cells to treat various solid tumors and refractory B cell
malignancies. Promisingly, the use of PD-1 knockout/disrupted CAR-T
cells in the treatment of cancer does not appear to increase the toxicity
profile as observed in the combination therapy using PD-1 blocking
mAbs and CAR-T cells. All available data to-date supports that combi-
nation of CAR-T cells with the disruption of endogenous inhibitory
immune checkpoint PD-1 by CRISPR-Cas9 technology represents a
promising immunotherapeutic modality for cancer treatment. The full
clinical potential of this new approach for the treatment of solid tumor
is too early to appreciate until more clinical trials are completed and
data assessed.
The strategy of using PD-1 gene knockout/disruption CAR-T cells to
treat solid tumors mainly relies on CAR-T cell, ICI and CRISPR-Cas9
technology. Future in-depth investigation into these three areas would
promote the development of intrinsic PD-1 blockade incorporation into
CAR-T cells as a single therapy. The strategy of blocking PD-1 by dis-
rupting the gene within the T cells of the patient has to date been de-
monstrated to be safe with a decrease in the immune-related adverse
effects associated with systemic checkpoint blockade [34]. Indeed, all
available pre-clinical and clinical data confirm that the safety profiles of
PD-1 KO are promising, providing a solid foundation to move this ap-
proach forward. Future direction, we envisage continued advancement
of a more user friendly, precision CRISPR-Cas9 engineered technology
playing an important role in ADT cell cancer immunotherapy in the
near future, despite presenting some challenges [140]. New break-
through in CAR-T cell therapy research such as discovery of novel
targets will evolve and advance CAR-T technology. For example, very
recently Du and colleagues developed CAR-T cells targeting B7-H3. The
anti-tumor activity (both in vitro and in vivo) of the new anti-B7-H3/
CAR-T cells is significantly enhanced without detectable side effects
[170]. With optimal CAR targets, the anti-tumor activity of CAR-T cell
combined with intrinsic PD-1 inhibition would further enhance treat-
ment efficacy. Barriers posed by the TME are slowly being removed,
CAR-T/PD-1 cells engineered with inbuilt safety mechanisms (suicide
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genes), improved specificity, reduced side effects, and improved effi-
cacy are also steps forward for solid tumor eradication.
Lastly, further understanding of solid tumor biology within the
TME, together with speedy genome editing technological advances in
PD-1 disrupted CAR-T cell biology to overcome multiple tumor eradi-
cation barriers, will lead to enhanced antitumor efficacy of immune-
based therapies. The biomanufacturing technology (such as manu-
facturing process automation) of CAR-T based therapeutic products is
evolving to meet the demanding clinical needs. The manufacturing time
of CAR-T cell products can be significantly shortened to one day. We
await the development of next generation allogeneic CAR /PD-1KO T
cells as a safe, personalized and economical therapy for all solid tumors.
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